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Abstract Despite the fact that mineralocorticoid receptor
(MR) antagonist drugs such as spironolactone and eplerenone
reduce the mortality in heart failure patients, there is, thus far,
no unambiguous demonstration of a functional role of MR in
cardiac cells. The aim of this work was to investigate the
activation pathway(s) mediating corticosteroid-induced up-
regulation of cardiac calcium current (ICa). In this study, using
neonatal cardiomyocytes from MR or glucocorticoid receptor
(GR) knockout (KO) mice, we show that MR is essential for
corticosteroid-induced up-regulation of ICa. This study
provides the first direct and unequivocal evidence for MR
function in the heart.
Keywords Corticosteroids . Nuclear receptors .
Aldosterone . Calcium current
Introduction
Adrenal corticosteroids [mineralocorticoids (MR) and glu-
cocorticoids (GR)] target many effector organs, including
the heart. The natural mineralocorticoid aldosterone and the
glucocorticoid cortisol (corticosterone in rodents) bind to
intracellular receptors, the high affinity MR, and the low
affinity GR, which are both expressed in cardiomyocytes
[2]. However, cardiomyocytes are defined as “nonclassical”
MR-expressing cells because the ligand specificity (aldo-
sterone vs cortisol/corticosterone) of the receptor remains
unclear. While in classical MR-expressing tissues, such as
the kidney and the colon, the MR is protected from
occupancy by glucocorticoids by the activity of the 11-β-
hydroxysteroid-dehydrogenase type-2 (11β-HSD2) that
converts cortisol/corticosterone into inactive metabolites;
cardiomyocytes demonstrate very low levels of this enzyme
[2]. This observation suggests that there is very little, if any,
“MR-protection” mechanism, which may circumvent MR
occupancy by glucocorticoids circulating at concentrations
>100-fold higher than aldosterone. Thus, in cardiomyo-
cytes, MR is most likely occupied only by glucocorticoids.
In the past few years, the beneficial effect of MR
antagonist drugs such as spironolactone and eplerenone in
heart failure patients has been clearly demonstrated [8].
However, the molecular mechanisms underlying these
clinical observations remain poorly understood. In particu-
lar, the role of MR activation or blockade in the heart is a
matter of debate. One of the key questions that have been
difficult to address is to what extent MR-mediated effects
can be dissociated from GR-dependent effects.
In the present study, we addressed whether MR or GR
activation is responsible for corticosteroid-induced up-
regulation of ICa [1] using MR or GR knockout mice. Our
experiments unequivocally demonstrate the essential role of
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MR in mediating the corticosteroid-dependent up-regulation
of ICa, thus providing the first demonstration of a functional
role of MR in cultured neonatal cardiac cells.
Materials and methods
Cell culture
Due to the early lethality of the MR and GR knockout
mice, the hearts (atria and ventricles) from newborn mice or
from mouse fetuses (day 18.5 of gestation, male and
female) were excised under sterile conditions and cut into
four equal parts. After extensive washing, these parts were
transferred into an Eppendorf tube containing 1 ml of
Hanks’ medium (Gibco/Invitrogen), supplemented with
0.5 mg/ml trypsin (USB). Incubation with trypsin lasted
overnight with gentle agitation (700 rpm, Eppendorf
Compact Thermomixer) at 4°C. At the end of the
incubation with trypsin, tissue was allowed to settle for
1 min, and the 500-μl trypsinization solution was removed
and replaced by 500 μl of Light medium composed of
Dulbecco’s modified Eagle’s medium (DMEM)/M-199
media (3/1, v/v), supplemented with 1/100 times diluted
(v/v) standard mix of penicillin/streptomycin/glutamine
(Gibco/Invitrogen), and 10 mM Hepes (pH 7.3). Tubes
were incubated for 2.5 min with gentle agitation
(1,100 rpm, Eppendorf Compact Thermomixer) at 37°C.
Tissue was allowed to settle, and medium was replaced by
250 μl of Hanks’ medium, supplemented with 300 U/ml
collagenase type 2 (Worthington Biochemical). Tubes were
incubated for 1.5 min with gentle agitation (1,100 rpm,
Eppendorf Compact Thermomixer) at 37°C. Medium was
discarded and replaced by a new 250-μl aliquot of Hanks’/
collagenase solution. Tubes were incubated for 7 min at
37°C (1,100 rpm, Eppendorf Compact Thermomixer). Medi-
umwas removed and mixed with 250 μl of Complete medium
composed of the Light medium supplemented with 10% horse
serum and 5% fetal calf serum (Gibco/Invitrogen). The
collagenase digestion step was performed two additional
times. The three fractions of cardiac cells were centrifuged
separately at 750×g for 5 min at 4°C. Medium was discarded
and cell pellets were pooled in 750 μl of Complete medium.
Cells were plated in a single well of a 24-well plate and
incubated for 1 h 15 min at 37°C (10% CO2). This step
allows attachment of fibroblasts to the well surface and their
separation from other cells. This step was repeated once. The
remaining cells were plated in two wells of a 24-well plate
coated with gelatin and fibronectin. In the resulting culture,
at least 85% of all cells were cardiomyocytes. The
cardiomyocytes were actively beating throughout the exper-
imental period (3 days). The MR(null/null) and GR(null/null)
neonatal mice were obtained by breeding of corresponding
heterozygous mice bearing one null and one wild-type allele
[5]. All animal experiments were carried out according to the
Swiss Animal Protection Law.
Electrophysiological procedures
Patch-clamp recordings in whole cell configuration were
carried out using an internal solution containing (mmol/l):
CsAsp 70, MgATP 5, CsCl 60, EGTA 11, HEPES 10,
MgCl2 1, pH 7.2 with CsOH; external solution: TEA-Cl
130, CaCl2 2, MgCl2 1.2, CsCl 5, HEPES 10, Glucose 5,
pH 7.4 with CsOH. The resistance of the pipettes was in the
range of 1.7–2.5 MΩ. Experiments were performed at RT
(22–23°C). A voltage-gated sodium channel blocker,
tetrodotoxin 30 μM, was added in the bath before the
recording of calcium current. Finally, to investigate the
different biophysical properties of the calcium channel,
the activation and the steady-state inactivation protocols
were performed.
Drugs
Tetrodotoxin was purchased from alomone (Jerusalem,
Israel). Aldosterone, corticosterone, fibronectin, and gelatine
type A were from Sigma (Buchs, Switzerland). Trypsin,
HBSS (ref 14170–070), DMEM, M-199, penicillin/strepto-
mycin/glutamine and HEPES were from Gibco (Basel,
Switzerland). Collagenase type II was purchased from
Worthington Biochemical (Allschwil, Switzerland).
Quantitative PCR analyses
Primary cultures of neonatal mouse cardiomyocytes were
either untreated (control) or stimulated for 24 h with
aldosterone (10−6 M). Total RNA was extracted and re-
verse transcribed using Superscript II reverse transcriptase
(Invitrogen). Real-time quantitative polymerase chain
reaction (PCR) analysis was performed using the TaqMan
system from Applied Biosystems. All reactions were
performed in triplicate. All primer sets used in this study
were from Applied Biosystems: TaqMan Gene Expression
Assay: PER1 Mm00501813_m1, Cav1.2 Mm00437917, and
mouse ACTB (β-actin) endogenous control (for β-actin).
Data analysis and statistics
Measurements were made using a VE-2 (Alembic Instru-
ments, Montreal, QC, Canada) amplifier. Data were
analyzed using pClamp software, version 8 (Axon Instru-
ments, Union City, California, USA) and KaleidaGraph
software (Synergy Software, Reading, PA). Peak currents
were measured using the protocol, and Ca2+ current (ICa)
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density (expressed as pA/pF) was obtained by dividing the
peak current by the cell capacitance obtained using the
pClamp function. After the acquisition, currents were
filtered at 25 Hz with low pass type Gaussian filter using
pClamp software, version 8 (Axon Instruments, Union City,
California, USA).
Two-tailed Student t test was used to compare two
groups. Statistical significance is set at P<0.05. Values are
expressed as means±SEM.
Results
Aldosterone-induced increase of ICa depends on MR,
but not GR, expression
First, we determined the effect of a 24-h incubation of
1 μM aldosterone on ICa of neonatal mouse cardiomyocytes
by performing whole-cell patch-clamp experiments
(Fig. 1a). Importantly, 1 μM aldosterone is predicted to
occupy both MR and GR, but to distinguish between MR-
and GR-mediated effects, myocytes prepared from either
MR- or GR-KO mice were used. The current elicited at
+10 mV is most likely due to L-channel activation [4]
(Fig. 1a). After aldosterone incubation, ICa was increased
by 86±22% (Fig. 1a,b and Table 1). In contrast, no
significant increase of ICa currents was observed in MR-
KO cells (7±17%, Fig. 1c,d and Table 1). Aldosterone-
induced up-regulation of ICa in GR-KO cardiomyocytes
was very similar to that observed using WT cells (+86±
13%, Fig. 1e,f and Table 1).
Biophysical properties of ICa are not modified
by aldosterone treatment
In parallel, ICa was also elicited by 200-ms step depolariza-
tions from a holding potential of −100 mV. Exposure of
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Fig. 1 Effect of aldosterone incubation on ICa on WT, MR, and GR-
KO myocytes. a, c, and e Holding potential was −100 mV. Gray dots
show the current from control cells, and the white dots show the
current from treated cells (24 h, 1 μM aldosterone). b, d, and f
Normalized ICa currents determined in cells treated as indicated. The
number of cells used is indicated within the bars; *P<0.05, **P<0.01,
n.s. Not significant. g, h, i Modulation of ICa by aldosterone on wt (g)
and KO (h and i) mouse cardiomyocytes. Current density–voltage
relationships of ICa in control myocytes (black dots) and after
aldosterone treatment (1 μM for 24 h; white dots); n=5–9 cells per
condition; *P<0.05, **P<0.01 vs control
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WT cardiomyocytes for 24 h to 1 μM aldosterone
significantly increased the inward ICa densities between
−20 and +20 mV (Fig. 1g), whereas it did not modify ICa of
MR-KO cells (Fig. 1h). In contrast, ICa density was
significantly increased between −10 and +10 mV in GR-
KO myocytes (Fig. 1i). No modification of the cell
capacitance was observed in WT, MR, and GR-KO
cells upon aldosterone incubation (Table 1). The voltage-
dependence of the steady-state inactivation and activation
were similar with or without aldosterone incubation, inde-
pendent of the genotype of the cardiomyocytes (Table 1).
Aldosterone EC50 for ICa up-regulation is consistent
with MR activation
As illustrated in Fig. 2a, the effect of aldosterone on ICa was
concentration dependent. A concentration–response anal-
ysis showed that the calculated EC50 values of the 24-h
aldosterone-induced increase of ICa (Fig. 2b) was 2.0 nM
(R2=0.99). This value is close to the Kd values (0.5–
2 nM) of aldosterone for the MR [2].
Effect of corticosterone and RNA expression of Cav1.2
channel subunit
In mice, the main glucocorticoid hormone is corticosterone,
whereas in humans, it is cortisol. Both hormones have a
similar affinity to the MR. Therefore, it could be expected that
ICa is also regulated by corticosterone. Corticosterone
incubation (1 μM, 24 h) increased ICa (+45±9%) (Fig. 2c,d).
Finally, to determine if the increase of L-type ICa is due
to an up-regulation of the mRNA encoding the Ca channel
alpha-subunit Cav1.2-CACNA1C, qPCR analyses using
specific probes have been performed. Aldosterone treat-
ment (1 μM, 24 h) did not increase the mRNA level of
Cav1.2, while the positive control gene Per1 [5] was
increased by greater than fivefold (Fig. 2e).
Discussion
In this study, we could unequivocally demonstrate a
functional role of endogenously expressed MR in cardiac
cells. This is based on two main lines of evidence. Firstly,
the EC50 value for the effect aldosterone on ICa was
~2 nM, which is within the 0.1–2 nM range of MR-
dependent aldosterone effects determined in different
studies [2]. Secondly, these effects were abolished in
myocytes of MR-deficient mice, but conserved in GR-
deficient cells. We also observed that the glucocorticoid
corticosterone increased the ICa, similarly to aldosterone.
Under physiologic conditions, it is very likely that the MR
is continuously occupied by the circulating glucocorticoids
when one considers that (1) in cardiomyocytes, the MR is
“unprotected” because of the low 11β-HSD2 activity, (2)
Table 1 The data from individual cells were fitted with Boltzmann relationship, y Vmð Þ ¼ 1

1þ exp Vm  V1=2
 
K
  
; in which y is the
normalized current or conductance, Vm is the membrane potential, V1/2 is the voltage at which half of the channels are activated or inactivated, and
K is the slope factor
Parameter Experiment Wild type MR-KO GR-KO
Cell capacitance (pF) Control 11.9±1.2 (n=12) 11.0±1.4 (n=8) 11.1±1.4 (n=8)
Aldosterone 11.4±0.8 (n=11) n.s. 10.2±0.9 (n=10) n.s. 9.9±0.7 (n=9) n.s.
Activation
K (mV) Control 11.8±1.1 (n=8) 9.9±0.9 (n=7) 10.9±2.7 (n=4)
Aldosterone 11.3±0.9 (n=9) n.s. 9.7±1.2 (n=5) n.s. 8.9±0.8 (n=7) n.s.
V1/2 (mV) Control −9.6±3.0 (n=8) −6.4±2.6 (n=7) −5.4±2.4 (n=4)
Aldosterone −8.2±2.2 (n=9) n.s. −7.8±1.4 (n=5) n.s. −6.9±1.1 (n=7) n.s.
Inactivation
K (mV) Control 9.4±0.6 (n=6) 8.7±1.7 (n=5) 8.2±0.7 (n=6)
Aldosterone 7.4±1.6 (n=5) n.s. 8.8±1.4 (n=5) n.s. 8.8 ±0.8 (n=8) n.s.
V1/2 (mV) Control −29.5 ±1.1 (n=6) −27.3 ±1.3 (n=5) −30.4 ±1.3 (n=6)
Aldosterone −28.3 ±1.6 (n=5) n.s. −29.2 ±1.3 (n=5) n.s. −31.0 ±0.8 (n=8) n.s.
ICa amplitude (pA/pF)
Control 5.2 ± 0.5 (n=12) 7.0±1.5 (n=8) 3.3±0.3 (n=8)
Aldosterone 9.7±1.1 (n=11) ** 7.6±1.2 (n=10) n.s. 6.1±0.4 (n=9) **
Peak ICa was measured at +10 mV during a classical protocol. Number of cells in parenthesis
n.s. Not significant vs control
*P<0.05
**P<0.01
relationship, y Vmð Þ ¼ 1

1þ exp Vm  V1=2
 
K
  
; in wh ch y is
the normaliz d current or conductance, Vm is the membrane potential,
V1/2 is the voltage at which half of the channels are a tivated or
inactivated, and K is the slope f ctor
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Kd of glucocorticoids–MR interaction is within the nano-
molar range, and (3) the circulating glucocorticoid concentra-
tion is ∼100 μM. However, whether the MR-glucocorticoid
interaction leads to only the activation of the receptor has been
recently challenged by Funder [3]. This author propose that
the degree of glucocorticoid-MR complex activity may
depend on the oxidation and reduction (redox) state of cells.
Under metabolic stress conditions, for instance during
reactive oxygen species production caused by ischemia, some
yet unknown mechanisms may activate the glucocorticoid-
occupied MR, which in contrast could be inactive under
resting/physiologic conditions. Obviously, these putative
mechanisms need to be investigated further.
There is no doubt that MR antagonist drugs are clinically
effective in reducing the mortality in heart failure patients
[8], by decreasing the incidence of sudden death. This
observation has led to the suggestion that the electrical
activity of the heart, which depends mainly on the function
of ion channels, can be regulated (or dysregulated) by
aldosterone. In keeping with this concept, recent studies
showed that incubating isolated cardiomyocytes with high
concentrations of aldosterone increased ICa [1,4]. However,
despite using MR and/or GR antagonists, it could never be
shown convincingly that the effects of aldosterone were
mediated only by the MR. Indeed in most studies, very high
concentrations of aldosterone were used (10–1,000 nM)
which may activate both MR and GR. In addition, most of
the drugs that were used are not completely specific for either
receptor. Here, using myocytes from GR or MR-KOmice, the
essential role of MR in mediating the corticosteroid-induced
increase of ICa could be demonstrated. These findings, in
combination with our recent work showing that the induction
of the enzyme Art3 by corticosteroids depends exclusively
on GR [5], demonstrate that the two receptor-mediated
pathways may function in parallel in cardiomyocytes.
How may these results influence our understanding of
the positive effect of MR antagonist drugs [8]? In mice, it
has been shown that high aldosterone concentrations and
cardiac-specific over-expression of MR prolong the dura-
tion of action potentials [7] and QT intervals of the ECG
[6]. This phenotype is most likely the result of a MR-
dependent electrical remodeling process leading to an
acquired form of long QT syndrome. It may be speculated
that MR antagonists are beneficial and, in particular, reduce
b
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Fig. 2 Concentration–response curves of aldosterone on ICa of WT
cardiomyocytes. a Traces of high-threshold calcium current of control
and aldosterone treated (1 nM and 1 μM, 24 h) cardiomyocytes. b
Concentration–response curve of aldosterone on ICa. Data from ICa
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indicated. The number of cells used is indicated within the bar; *P<
0.05, **P<0.01. e RNA-fold change of Cav1.2 and Per1 from either
control (untreated) or treated (1 μM, 24 h aldosterone) cardiomyo-
cytes. Expression levels were normalized to actin. The experiment was
performed in triplicate; ***P<0.001, n.s. Not significant
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the rate of sudden death because they interfere with this
deleterious electrical remodeling process.
In conclusion, the findings of this study demonstrate the
essential role of MR in aldosterone-induced up-regulation
of ICa. However, extrapolation to the in vivo and clinical
setting is limited, as we have no information about the role
of MR activation by glucocorticoids. Moreover, one has to
be cautious when trying to extrapolate such results, as they
have been obtained from experiments performed using
cultured neonatal cardiac cells that are obviously not
recapitulating the in vivo or adult complexity. More
experiments will be needed to understand further the
multiple mechanisms underlying the beneficial effects of
MR-antagonist drugs on the occurrence of sudden cardiac
death.
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